ArticlePain2017

CRISPR/Cas9 editing of Nf1 gene identifies CRMP2 as a therapeutic target in neurofibromatosis type 1-related pain that is reversed by (S)-Lacosamide.

Aubin Moutal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.